New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
13:30 EDTPRGOPerrigo confirms FDA approval of testosterone gel 1%
Perrigo Company (PRGO) announced that it has received U.S. Food and Drug Administration approval for its New Drug Application for testosterone gel 1%. Perrigo's NDA included a bioequivalence study that compared its product to AbbVie's AndroGel 1%. AndroGel 1% (testosterone gel 1%) is indicated to treat adult males who have low or no testosterone. Annual sales were approximately $705M annually, as measured by Symphony Health. Perrigo's Chairman and CEO Joseph C. Papa stated, "This filing is another example of our investment in new products and continued focus on bringing extended topicals to market. As always, Perrigo is committed to making quality healthcare more affordable for our customers and consumers."
News For PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
11:33 EDTPRGOPerrigo management to meet with Jefferies
Subscribe for More Information
07:45 EDTPRGOFDA to hold a public meeting
Subscribe for More Information
March 26, 2015
07:30 EDTPRGODeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 23, 2015
10:00 EDTPRGOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:25 EDTPRGOPerrigo downgraded to Sector Perform from Outperform at RBC Capital

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use